Pfizer Q2 Revenue Beat and Full-Year EPS Guidance Miss
Pfizer reported Q2 revenues of $14.45 billion, up 5.4% year over year, and beat analysts’ revenue and EPS estimates. The quarter was mixed, however, as full-year EPS guidance was missed. Peer results also offered context as Corcept and Bristol-Myers Squibb posted differing revenue outcomes and Pfizer shares rose heading into earnings.